MedTrace Logo

Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

NCT01358383 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2012-06-22

No results posted yet for this study

Summary

This is an assessment of Pharmacokinetics of a single oral dose of VIMOVO in healthy adult volunteers.

Conditions

  • Juvenile Idiopathic Arthritis

Interventions

DRUG

naproxen

250mg, oral dose

DRUG

esomeprazole

20mg, oral dose

Sponsors & Collaborators

Principal Investigators

  • Mark Sostek · AstraZeneca

  • Bo Fransson · AstraZeneca

  • Kelly Craven · Quintiles Phase I Services, Overland Park, Kansas

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01358383 on ClinicalTrials.gov